Briefings

What is changing in the rules, what it means for your product, your municipality or your project, and who here handles it. In English and Portuguese.

Monitoring reports, cosmetic products

Our monitoring reports record the changes to cosmetics rules in a given period, and we publish one each month. Each one is a dated publication: it reflects the rules on the date it was published and is not updated afterwards. For what applies today, read the latest briefings or ask us.

210 items

Results

Monitoring report

Final SCCS opinion on Alpha-arbutin and Beta-arbutin

Ingredients: ALPHA-ARBUTIN, BETA-ARBUTIN

Date of publication: 01/02/2023

On February 1, 2023, the Scientific Committee on Consumer Safety (SCCS) published its final opinion on the use of alpha-arbutin and betaa-arbutin in cosmetic products.

Monitoring report

Draft regulation on microplastics in cosmetic products

Topic: Microplastics regulation in European Union

Date of publication: 30/08/2022 (draft)

On August 30, 2022, the European Commission released a draft proposal to restrict intentionally added microplastics. The restriction would comprise synthetic polymer microparticles below 5 mm and fiber-like particles below 15 mm that are used in products on intention and may result in environmental release.

Monitoring report

Spain revokes mandatory Green Dot labelling for packaging

Topic: Green Dot labelling in Spain

Date of publication: 27/12/2022

Date of application: 01/01/2025

Spanish Royal Decree 1055/2022 will apply as of January 1, 2025, introducing several new requirements on packaging.

Monitoring report

Entry into force of the new restrictions on UV filters Octocrylene and Benzophenone-3

Ingredients: BENZOPHENONE-3, OCTOCRYLENE

Date of publication: 07/07/2022

Date of application: 28/01/2023 (placing on the market); 28/07/2023 (sell-off)

Regulation (EU) 2022/1176 amends Regulation (EC) No 1223/2009, restricting the use of Benzophenone-3 and Octocrylene as UV filters in cosmetic products.

Monitoring report

51st Amendment to IFRA Standards expected in June 2023

Ingredients: COSMETIC FRAGRANCES and AROMATIC COMPOSITIONS

Date of publication: Expected in June 2023

IFRA is preparing the 51st Amendment to its standards. The proposed amendment is open for consultation until February 28, 2023, in order to give the industry the opportunity to submit its comments. Official notification of the 51st Amendment is expected in June 2023.

Monitoring report

Regulation (EU) 2022/2195 – Updates to cosmetic ingredients use requirements

Ingredients: BHT, ACID YELLOW 3, HOMOSALATE, HAA299 and RESORCINOL

Date of publication: 11/11/2022

Date of application: 01/07/2023

Commission Regulation (EU) 2022/2195 of November 2022 amends Regulation (EC) No 1223/2009, restricting the use of BHT, Acid Yellow 3, Homosalate, HAA299 and Resorcinol, in cosmetic products.

Cosmetic Products

Monitoring report

European Commission requests SCCS Opinion on the safety of Cyclamen Aldehyde

Ingredient: CYCLAMEN ALDEHYDE

Date of publication: 8 June 2026

The Scientific Committee on Consumer Safety (SCCS) has accepted a mandate to assess the safety of Cyclamen Aldehyde, following potential classification as a reproductive toxicant under the CLP Regulation.

Monitoring report

European Cosmetics Regulation – Updates on Cosmetic Ingredients  

Topic: NEW RESTRICTIONS ON COSMETIC INGREDIENTS

Date of publication: 13 January 2026

The European Commission published Commission Regulation (EU) 2026/78, which brings new restrictions on several cosmetic ingredients that were classified as Carcinogenic, Mutagenic or Toxic for Reproduction (CMR).

Monitoring report

United Kingdom publishes Technical Report on the Classification and Labelling of Talc 

Ingredient: TALC

Date of publication: January 2026

The United Kingdom (UK) Health and Safety Executive (HSE) has published a technical report concluding that Talc does not warrant carcinogenicity classification, diverging from ECHA's Risk Assessment Committee (RAC) opinion supporting Category 1B classification.

Medical Devices

EU

How to demonstrate equivalence under the MDR

Clinical data from an equivalent device can support your clinical evaluation, but the MDR sets a higher bar than the Directives did. The three characteristics, data access, and documentation.

Follow an area

One email when an area publishes, in the language you choose. Nothing else.